Tesamorelin: from HIV lipodystrophy to off-label visceral fat research

The only FDA-approved GHRH analog has an unusual origin story — and an increasingly interesting research trajectory outside its original indication.

TL;DR

• Tesamorelin (brand name Egrifta) was developed for HIV-related fat redistribution and is the only GHRH-class peptide with FDA approval.
• Its mechanism — stimulating the pituitary to release growth hormone — is the same biological pathway as CJC-1295 and sermorelin.
• Off-label research in non-HIV adults shows effects on visceral fat and IGF-1, but this use requires a physician evaluation and is not its approved indication.

What it is

Tesamorelin is a GHRH analog (in plain English: a synthetic version of growth hormone-releasing hormone — the signal your hypothalamus sends to the pituitary gland to release growth hormone). It works by mimicking the body’s natural GHRH signal, prompting the pituitary to release its own GH in a physiologically pulsatile (rhythmic, burst-based) pattern — rather than administering GH directly.

Unlike most research peptides, tesamorelin has gone through full FDA clinical trials and received approval in 2010 for a specific indication: excess abdominal fat accumulation (lipodystrophy — abnormal fat redistribution) in adults with HIV.

How it works

The mechanism is the same as other GHRH-class secretagogues: tesamorelin binds to GHRH receptors on pituitary cells (the key enters the lock), triggering GH release. The GH then signals the liver to produce IGF-1, which mediates many of the downstream effects on metabolism and body composition — including effects on visceral adipose tissue (the fat stored around internal organs, associated with metabolic risk).

In HIV-positive patients with lipodystrophy, phase 3 trials showed tesamorelin reduced visceral adipose tissue by about 15–18% over 26 weeks compared to placebo (JCEM, 2010).

Why it’s relevant beyond HIV

In HIV patients, the visceral fat accumulation tesamorelin targets is driven partly by antiretroviral therapy and partly by GH axis suppression — both of which increase visceral fat. Researchers noted that the same mechanism (GH axis stimulation reducing visceral fat) might apply in non-HIV adults with age-related visceral fat accumulation.

Studies in healthy older adults have since confirmed that tesamorelin raises IGF-1 and is associated with reductions in visceral fat, though the effect sizes and clinical significance in non-HIV populations are an active area of investigation.

Who asks about it

People in longevity or performance medicine contexts who’ve heard about tesamorelin and want to understand how it differs from CJC-1295 or sermorelin — and why it has an FDA approval when similar peptides don’t.

What to know before considering it

Tesamorelin is a prescription-only compound. Its FDA approval is for HIV lipodystrophy; use outside that indication is off-label. Off-label use is legal and common in medicine but requires a clinician to evaluate the clinical rationale. IGF-1 and body composition baselines (ideally a DEXA scan for visceral fat measurement) are appropriate before starting. See our DEXA body composition explainer.

The Halftime POV

Tesamorelin is interesting partly because it has the most robust clinical evidence of any GHRH-class peptide — the FDA approval process generated trial-quality data. That evidence base doesn’t automatically transfer to the off-label use case, but it provides more clinical signal than a purely preclinical compound does.

Related reading:

• What IGF-1 measures and why it matters
• CJC-1295: mechanism, research, and clinical context
• DEXA body composition testing explained

FAQ

Q: What is tesamorelin FDA-approved for? A: HIV-related lipodystrophy (abdominal fat accumulation) in adults. This is its only FDA-approved indication.

Q: Can tesamorelin be used for visceral fat in people without HIV? A: Yes, as off-label use with a physician evaluation and prescription. Published research shows effects on visceral fat and IGF-1 in non-HIV adults, but this is an emerging research area, not an approved indication.

Q: How does tesamorelin compare to CJC-1295? A: Both are GHRH-class peptides that stimulate the pituitary to release GH. Tesamorelin is a more direct GHRH analog; CJC-1295 includes a DAC (Drug Affinity Complex) modification that extends its half-life. Tesamorelin has FDA-trial data; CJC-1295 does not.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• FDA — Egrifta (tesamorelin) label, 2010
• Falutz J et al., “Metabolic effects of a growth hormone-releasing factor in patients with HIV,” NEJM, 2007

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health’s published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.